Market Research Reports

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

121pages
Published Date: 2014-09-01
 

Description


This report on hospital infection therapeutics, studies the current as well as future prospects of the market globally. Hospital infections are also referred to as healthcare-associated infections (HCAIs), or nosocomial infections or hospital-acquired infection (HAIs). HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission. A Hospital infection also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Several antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally prevalent at present. This report comprises of an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments that are contained in the report. It also provides an overall information and data analysis of the global hospital infection therapeutics market with respect to market segments based on type of drugs used, major hospital infections and geographic regions.

The market for hospital infection therapeutics is segmented into three major therapeutic drug types, namely, antibacterial, antiviral and antifungal drugs. The hospital infection therapeutics market is also segmented on the basis of major hospital infection types, into six major categories, namely, hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. The market has been extensively analyzed on the basis of the usefulness, effectiveness and sales revenue of major drug types as well as geographic prevalence of major types of hospital infections. The market size and forecast in terms of USD million for each drug as well as major infection types has been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. 

Geographically, the hospital infection therapeutics market has been categorized into four regions namely, North America, Europe, Asia Pacific, and Rest of the World (ROW). The market size and forecast for each of these regions has been provided for the period 2012 to 2020 along with the CAGR for the forecast period 2014 to 2020. The report also comprises a section on pipeline analysis for this market that includes sales forecast for various drugs currently under phase III clinical trials and expected to be launched during the forecast period. Major pipeline drugs that have been included in the report are Amikacin Inhale, CAZ AVI, Ceftolozane/Tazobactam, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin and Tedizolid. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of this market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter’s five forces analysis and competitive analysis of the key players in 2013 in the global hospital infection therapeutics market.

A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the hospital infection therapeutics market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi.

The global hospital infection therapeutics market is segmented as follows:

Hospital Infection Therapeutics Market, by Drug Type
  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs
Hospital Infection Therapeutics Market, by Major Infections
  • Hospital-Acquired Pneumonia
  • Surgical Site Infections
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Other Hospital Infections
Hospital Infection Therapeutics Market, by Geography
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents


Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Hospital Infection Therapeutics Market
2.2 Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)

Chapter 3 Hospital Infection Therapeutics Market Overview
3.1 Introduction
3.2 Event Impact Analysis
3.3 Market Drivers
      3.3.1 High Prevalence of Various Hospital Infections Driving the Demand for Anti-infective Drugs
      3.3.2 High Susceptibility of Neonatal Population in a Healthcare Setting Giving Rise to Different Hospital Infections
      3.3.3 Lack of Skilled Nursing Staff in Developing and Underdeveloped Economies is Increasing the Prevalence of HAIs
3.4 Market Restraints
      3.4.1 Increasing Hospital Surveillance and Infection Control Programs in Developed Countries Leading to a Decline in Number of Hospital Infections
      3.4.2 Increasing Number of Multi-drug resistant Bacterial Strains making Presently Available Antibacterial Drugs Obsolete
3.5 Market Opportunities
      3.5.1 High Number of Pipeline Drug Molecules for Specific Treatment of HAIs
      3.5.2 Increasing Incidences of Hospital Infections and High Unmet Needs in Low to Medium Income Countries of the World
3.6 Value Chain Analysis
3.7 Porter’s Five Forces Analysis: Global Hospital Infection Therapeutics Market
      3.7.1 Bargaining Power of Suppliers
      3.7.2 Bargaining Power of Buyers
      3.7.3 Threat of Substitutes
      3.7.4 Threat of New Entrants
      3.7.5 Competitive Rivalry
3.8 Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography
3.9 Competitive Landscape
      3.9.1 Market Share Analysis by Key Players: Hospital Infection Therapeutics Market, 2013 (Value %)

Chapter 4 Hospital Infection Therapeutics Market, by Drug Type
4.1 Overview
      4.1.1 Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 – 2020 (USD Million)
      4.1.2 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)
4.2 Antibacterial Drugs
      4.2.1 Global Antibacterial Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)
4.3 Antiviral Drugs
      4.3.1 Global Antiviral Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)
4.4 Antifungal Drugs
      4.4.1 Global Antifungal Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)
4.5 Pipeline Analysis: Market Forecast
      4.5.1 Amikacin Inhale
              4.5.1.1 Global Amikacin Inhale Market Revenue (Expected), 2016 – 2020 (USD Million)
      4.5.2 CAZ AVI (Ceftazidime/avibactum)
               4.5.2.1 Global CAZ AVI Market Revenue (Expected), 2015 – 2020 (USD Million)
      4.5.3 Ceftolozane/Tazobactam
               4.5.3.1 Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 – 2020 (USD Million)
      4.5.4 Dalvance (dalbavancin)
              4.5.4.1 Global Dalvance (dalbavancin) Market Revenue (Expected), 2016 – 2020 (USD Million)
      4.5.5 Delafloxacin (RX-3341)
              4.5.5.1 Global Delafloxacin Market Revenue (Expected), 2015 – 2020 (USD Million)
      4.5.6 Eravacycline (TP-434)
              4.5.6.1 Global Eravacycline Market Revenue (Expected), 2017 – 2020 (USD Million)
      4.5.7 MK-3415A
              4.5.7.1 Global MK-3415A Market Revenue (Expected), 2016 – 2020 (USD Million)
      4.5.8 Oritavancin
               4.5.8.1 Global Oritavancin Market Revenue (Expected), 2017 – 2020 (USD Million)
      4.5.9 Plazomicin
               4.5.9.1 Global Plazomicin Market Revenue (Expected), 2017 – 2020 (USD Million)
      4.5.10 Surotomycin (CB-315)
                4.5.10.1 Global Surotomycin Market Revenue (Expected), 2017 – 2020 (USD Million)
      4.5.11 Tedizolid (TR-701)
                4.5.11.1 Global Tedizolid Market Revenue (Expected), 2015 – 2020 (USD Million)

Chapter 5 Hospital Infection Therapeutics Market, by Major Infections
5.1 Overview
      5.1.1 Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 – 2020 (USD Million)
      5.1.2 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)
5.2 Hospital-Acquired Pneumonia (HAP)
      5.2.1 Global HAP Therapeutics Market Revenue, 2012 – 2020 (USD Million)
5.3 Surgical Site Infections (SSIs)
      5.3.1 Global Surgical Site Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)
5.4 Urinary Tract Infections (UTIs)
      5.4.1 Global UTI Therapeutics Market Revenue, 2012 – 2020 (USD Million)
5.5 Gastrointestinal Disorders
      5.5.1 Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 – 2020 (USD Million)
5.6 Bloodstream Infections
      5.6.1 Global Bloodstream Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)
5.7 Other Hospital Infections
      5.7.1 Global Other Hospital Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)

Chapter 6 Hospital infection therapeutics Market, by Geography
6.1 Overview
      6.1.1 Global Hospital infection therapeutics Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
      6.2.1 North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.3 Europe
      6.3.1 Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
      6.4.1 Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
      6.5.1 RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Recommendations

Chapter 8 Company Profiles
8.1 Actavis plc
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 AstraZeneca plc
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 Bayer AG
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 Bristol-Myers Squibb Company
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 Cubist Pharmaceuticals, Inc.
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 GlaxoSmithKline plc
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 Johnson & Johnson Services, Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Merck & Co., Inc.
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments
8.9 Pfizer, Inc.
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
      8.9.5 Recent Developments
8.10 Sanofi
      8.10.1 Company Overview
      8.10.2 Financial Overview
      8.10.3 Product Portfolio
      8.10.4 Business Strategies
      8.10.5 Recent Developments

List of Figures

FIG. 1 Hospital Infection Therapeutics: Market Segmentation
FIG. 2 Global Hospital Infection Therapeutics Market, by Drug Type, 2013 (USD Million)
FIG. 3 Global Hospital Infection Therapeutics Market, by Major Infections, 2013 (USD Million)
FIG. 4 Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)
FIG. 5 Global Hospital Infection Therapeutics Market: Event Impact Analysis
FIG. 6 Global Hospital Infection Therapeutics Market, Value Chain Analysis
FIG. 7 Porter’s Five Forces Analysis: Global Hospital Infection Therapeutics Market, 2012 - 2020
FIG. 8 Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography (2013)
FIG. 9 Market Share Analysis: Hospital Infection Therapeutics Market, 2013 (Value %)
FIG. 10 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)
FIG. 11 Global Antibacterial Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Antiviral Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Antifungal Drugs in HIT Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Amikacin Inhale Market Revenue (Expected), 2016 – 2020 (USD Million)
FIG. 15 Global CAZ AVI Market Revenue (Expected), 2015 – 2020 (USD Million)
FIG. 16 Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 – 2020 (USD Million)
FIG. 17 Global Dalvance (Dalbavancin) Market Revenue (Expected), 2016 – 2020 (USD Million)
FIG. 18 Global Delafloxacin Market Revenue (Expected), 2015 – 2020 (USD Million)
FIG. 19 Global Eravacycline Market Revenue (Expected), 2017 – 2020 (USD Million)
FIG. 20 Global MK-3415A Market Revenue (Expected), 2016 – 2020 (USD Million)
FIG. 21 Global Oritavancin Market Revenue (Expected), 2017 – 2020 (USD Million)
FIG. 22 Global Plazomicin Market Revenue (Expected), 2017 – 2020 (USD Million)
FIG. 23 Global Surotomycin Market Revenue (Expected), 2017 – 2020 (USD Million)
FIG. 24 Global Tedizolid Market Revenue (Expected), 2015 – 2020 (USD Million)
FIG. 25 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)
FIG. 26 Global HAP Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 27 Global Surgical Site Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 28 Global UTI Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 29 Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 30 Global Bloodstream Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 31 Global Other Hospital Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 32 North America Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 33 Europe Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 34 Asia Pacific Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 35 RoW Hospital infection therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 36 Actavis plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 37 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 38 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 39 Bristol-Myers Squibb Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 40 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 41 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 42 Johnson & Johnson: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 43 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 44 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 45 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Hospital Infection Therapeutics Market
TABLE 2 Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 – 2020 (USD Million)
TABLE 3 Comparison of Major Resistant Bacterial Strains Prevalence Against Major Therapeutic Drug Classes, in Respective Years (2008 & 2013)
TABLE 4 Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 – 2020 (USD Million)
TABLE 5 Global Hospital infection therapeutics Market Revenue, by Geography, 2012 – 2020 (USD Million)

Enquiry Before Buying


Free Market Analysis


Hospital infection is also referred to as healthcare-associated infection (HCAI) or nosocomial infection or hospital-acquired infection (HAI). HAI are those infections that develop in patients undergoing treatment in a healthcare setting, it also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. According to the Centers for Disease Control and Prevention (CDC), in 2011, approximately 1.7 million HAIs from all types of bacteria combined are reported each year in the U.S. In addition, according to the ECDC estimates, in 2013 around 4.1 million patients were diagnosed with HAI in Europe (including 30 nations).

Global hospital infection therapeutics market has been classified into three major segments, based on the type of drugs, namely, antibacterial, antiviral and antifungal drugs. In 2013, the antibacterial drugs segment held the largest share (70.7%) in the global hospital infection therapeutics market. Antibacterial drugs segment is also expected to be the fastest growing segment in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. The global hospital infection therapeutics market has been also classified into six major segments, based on the type of major hospital infections, namely, hospital-acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. In 2013, the hospital-acquired pneumonia segment held the largest share (over 20%) in the global hospital infection therapeutics market. Urinary tract infections segment is expected to be the fastest growing segment during the forecast period 2014 to 2020.

Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future.

North America dominates the global hospital infection therapeutics market followed by the European market in 2013. Key factors contributing to the growth of the region are high prevalence of various hospital infections, rising number of multi-drug resistant microbial pathogens, increasing demand for advanced therapeutics, and high ratio of hospitals per thousand of the population. This region also comprises huge geriatric population that are more prone towards different hospital infections due to their lowered immunity levels, hence require use of various antimicrobial therapeutics, which in turn will contribute towards the growth of this market. Asia-Pacific represents the fastest growing geographic region in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. Key factor responsible for the rapid growth of this market is increasing prevalence of hospital-acquired infections in the region. Increasing healthcare awareness and infrastructure along with increasing purchasing power of the people will add to the growth of this market in the region.

Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi are some of the major players operating in the global hospital infection therapeutics market. Most of these players constantly innovate and develop new, improved and/or advanced therapeutic drugs that cater to a larger audience worldwide to maintain their position in the global market.  

global-hospital-infection-therapeutics-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research